Medicago, GSK tout positive COVID-19 vaccine results

By The Science Advisory Board staff writers

May 19, 2021 -- Medicago and GlaxoSmithKline (GSK) announced positive interim phase II results for their adjuvanted COVID-19 vaccine candidate.

Medicago's plant-based vaccine, coronavirus viruslike particle (CoVLP), which has been tested with GSK's adjuvant, showed a similar antibody response in adults and elderly individuals after they received two doses. Those vaccinated experienced neutralizing antibody responses that were 10 times higher than those who were recovering from the novel coronavirus.

No severe adverse events were reported, according to the companies.

The companies launched the phase III trial of the vaccine candidate in March 2021 and will enroll up to 30,000 individuals worldwide.

Copyright © 2021

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for

Email Preferences

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.